At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses recent advances in the management of ovarian cancer, including the use of the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, as maintenance therapy for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.